This innovative text explores the cellular transport of organic cations, from functional and structural properties to pharmacological implications and psychiatric developments. The authoritative chapters introduce organic cation transporters and then proceed to discuss their mechanisms such as binding of substrates and inhibitors; their drug dispositions and toxicity; their relationships to genetic and pathophysiological variability; and their roles in endocrine, metabolic, and neurological systems. The final chapters delve into the use of animal models for the study of organic cation transporter function and their possible use in environmental cycling of pharmaceutical residues. This comprehensive volume unites integrative transporter physiology with structural and molecular biology, genetics, pharmacology and pathophysiology, offering a holistic approach to utilizing this novel technique in physiological contexts. It will prove invaluable reading for researchers and students in various areas of integrative, organ, cell and molecular physiology as well as pharmacologists and neurologists.

This book discusses cancers and the resurgence of public interest in plant-based and herbal drugs. It also describes ways of obtaining anti-cancer drugs from plants and improving their production using biotechnological techniques. It presents methods such as cell culture, shoot and root culture, hairy root culture, purification of plant raw materials, genetic engineering, optimization of culture conditions as well as metabolic engineering with examples of successes like taxol, shikonin, ingenol mebutate and podophylotoxin. In addition, it describes the applications and limitations of large-scale production of anti-cancer compounds using biotechnological means. Lastly, it discusses future economical and eco-friendly strategies for obtaining anti-cancer compounds using biotechnology.

This volume focuses on antibiotics research, a field of topical significance for human health due to the worrying increase of nosocomial infections caused by multi-resistant bacteria. It covers several basic aspects, such as the evolution of antibiotic resistance and the influence of antibiotics on the gut microbiota, and addresses the search for novel pathogenicity blockers as well as historical aspects of antibiotics. Further topics include applied aspects, such as drug discovery based on biodiversity and genome mining, optimization of lead structures by medicinal chemistry, total synthesis and drug delivery technologies. Moreover, the development of vaccines as a valid alternative therapeutic approach is outlined, while the importance of epidemiological studies on important bacterial pathogens, the problems arising from the excessive use of antibiotics in animal breeding, and the development of innovative technologies for diagnosing the "bad bugs" are discussed in detail. Accordingly, the book will appeal to researchers and clinicians alike.

"Progress in Medicinal Chemistry" provides a review of eclectic developments in medicinal chemistry. This volume continues in the serial's tradition of providing an insight into the skills required of the modern medicinal chemist; in particular, the use of an appropriate selection of the wide range of tools now available to solve key scientific problems.
"Progress in Medicinal Chemistry" provides a review of eclectic developments in medicinal chemistry. This volume continues in the serial's tradition of providing an insight into the skills required of the modern medicinal chemist; in particular, the use of an appropriate selection of the wide range of tools now available to solve key scientific problems.

Reviews current methodology for assessing the health status of patients - their "quality of life" - and shows how this methodology can be applied to specific diseases such as cancer, rheumatoid arthritis, angina and Parkinson's disease. The text includes chapters on the Nottingham health profile, assessing quality of life in major disease areas, the importance of quality of life in policy decisions and development, testing and use of the sickness impact profile.

Mechanism of Action and Rationale for the Use of Biological Response Modifiers, Differentiating Agents and Nucleoside Analogues in Combination: Cytokine Synergy in Immunotherapy (J.W. Hadden et al.). Monitoring Combination Therapy Trials (J.L. Rossio et al.). Combination Chemotherapy and BRM Therapy in the Treatment of Cancer: Cancer Immunochemotherapy (G. Graziani et al.). Combination of Chronic Indomethacin and Intermittent IL2 Therapy in the Treatment of Disseminated Cancer (P.K. Lala et al.). Biological Response Modifiers and Differentiating Agents in Myelodisplastic Syndromes (A. Venditti et al.). Single and Combination Therapy with BRM's in the Treatment of Infectious Diseases, AIDS, and Autoimmunity: AntiCytokine Therapy of Murine Candidiasis (L. Romani et al.). The Basic Research and Clinical Application of Thymopeptidin (C.X. Zheng et al.). Combination AntiHIV Therapy (T.C. Merigan). 22 additional articles. Index.

This is the first book on the market that explores the importance of curcumin for the treatment of neurological disorders. It has been estimated that 35.6 million people globally had dementia in 2010 and the prevalence of dementia has been predicted to double every 20 years. Thus, 115.4 million people may be living with dementia in 2050. Alzheimer's disease (AD) is the leading cause of dementia and is present in 60%-70% of people with dementia. Unless new discoveries are made in the prevention or treatment of AD, the number of cases in the US alone is estimated to increase threefold, to 13.2 million by the year 2050. Thus, it is important to focus on delaying and treating the onset of AD by curcumin may be an important step for controlling AD. Regular consumption of healthy diet containing curcumin enriched foods, moderate exercise, and regular sleep may produce beneficial effects not only on motor and cognitive functions, but also on memory deficits that occur to some extent during normal aging and to a large extent in AD. Delaying the onset and progression of AD and improving its symptoms by few years with regular consumption of curcumin may relieve some of the burden on health care systems. In service of this goal, this volume gives readers a comprehensive and cutting edge description of the importance of curcumin for the treatment of AD in cell culture and animal models in a manner that is useful not only to students and teachers but also to researchers, dietitians, nutritionists and physicians. It can be used as supplement text for a range of neuroscience and nutrition courses. Clinicians, neuroscientists, neurologists and pharmacologists will find this book useful for understanding molecular aspects of AD treatment by curcumin.

Psychiatry Under the Influence investigates the actions and practices of the American Psychiatric Association and academic psychiatry in the United States, and presents it as a case study of institutional corruption.

This detailed volume provides a single, valuable reference source for methods that definitively identify and accurately quantify apoptosis. The book begins with common methods utilized to detect and quantitate apoptosis, as well as apoptosis signaling pathways in toxicological and other related research. It continues with multi-parametric and phased apoptosis assays for detecting early and late apoptosis or distinguishing apoptosis from necrosis and autophagy. Subsequent chapters focus on recent advances in real time and high-throughput assays that detect and quantitate apoptosis and apoptosis signaling pathways. Final chapters focus on recent developments in preclinical anticancer therapeutics targeting apoptosis. Written for the Methods in Pharmacology and Toxicology series, chapters feature step-by-step descriptions of the methodologies, as well as expert tips and implementation advice. Vital and authoritative, Apoptosis Methods in Toxicology serves novice scientists as well as experts, utilizing a range of instruments from common laboratory equipment to high-end expensive and automated machinery capable of performing real time apoptotic measurements.

Synthesis of Essential Drugs describes methods of synthesis, activity and implementation of diversity of all drug types and classes. With over 2300 references, mainly patent, for the methods of synthesis for over 700 drugs, along with the most widespread synonyms for these drugs, this book fills the gap that exists in the literature of drug synthesis. It provides the kind of information that will be of interest to those who work, or plan to begin work, in the areas of biologically active compounds and the synthesis of medicinal drugs. This book presents the synthesis of various groups of drugs in an order similar to that traditionally presented in a pharmacology curriculum. This was done with a very specific goal in mind - to harmonize the chemical aspects with the pharmacology curriculum in a manner useful to chemists. Practically every chapter begins with an accepted brief definition and description of a particular group of drugs, proposes their classification, and briefly explains the present model of their action. This is followed by a detailed discussion of methods for their synthesis. Of the thousands of drugs existing on the pharmaceutical market, the book mainly covers generic drugs that are included in the WHO's Essential List of Drugs. For practically all of the 700+ drugs described in the book, references (around 2350) to the methods of their synthesis are given along with the most widespread synonyms. Synthesis of Essential Drugs is an excellent handbook for chemists, biochemists, medicinal chemists, pharmacists, pharmacologists, scientists, professionals, students, university libraries, researchers, medical doctors and students, and professionals working in medicinal chemistry.

Founded in 1959, the series has moved from its initial focus on medicinal chemistry to a much wider scope. This volume encompasses all fields concerned with the development of therapeutic drugs, and the elucidation of their mechanisms of action. When combined with the other volumes, it serves as a time-saving source of information for researchers concerned with drug research, and all those who need to keep abreast of ongoing developments in medicines.

This text provides a practical guide providing step-by-step protocol to design and develop vaccines. Chapters detail protocols for developing novel vaccines against infectious bacteria, viruses, fungi, and parasites for humans and animals. Volume 1: Vaccines for Human Diseases has an introductory section on how vaccines impacted diseases, the immunological mechanism of vaccines, future challenges for vaccinologists, and current trends in vaccinology. The design of human vaccines for viral, bacterial, fungal, parasitic and prion diseases as well as vaccines for drug abuse, allergy, and tumor vaccines are also described in this volume. As a volume in the highly successful Methods in Molecular Biology series, chapters contain introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and practical, Vaccine Design: Methods and Protocols, Volume 1: Vaccines for Human Diseases aims to ensure successful results in the further study of this vital field.

This international directory of pharmaceutical manufacturers includes 1,046 firms in 50 countries. They are arranged alphabetically by country and company name.

In addition to name and address, other information such as telephone and fax number, and key personnel are also listed, where available.

Completing the directory, is a listing of 124 Contract Manufacturers in 19 countries of ethical and/or non-prescription pharmaceuticals. These are arranged alphabetically by country and company name.

Current pharmaceutical and clinical approaches to the treatment of disease suffer from the inherent limitations in the specialization of drugs introduced to physiological systems. The interface of clinical and material sciences has allowed for a broad spectrum of creative approaches with the potential to alleviate these shortcomings. However, the synergy of these disciplines also presents problems in which nascent technology lacks the necessary evaluation within its intended clinical environment. Given the growing potential for materials science to address a number of unanswered therapeutic needs, it remains even more pressing to validate emerging drug delivery technologies in actual clinical environments. Drug Delivery: Materials Design and Clinical Perspective addresses the core fundamentals of drug delivery using material science and engineering principles, and then applies this knowledge using prominent examples from both the scientific literature and clinical practice. Each chapter focuses on a specific drug delivery technology, such as controlled-release materials, thin-film materials, or smart materials. Within each chapter, an initial section on "Engineering Concepts" reviews the relevant fundamental principles that guide rational design. The following section on "Materials Design" discusses how the design process applies engineering concepts for use in physiological systems. A third section on "Implementation" discusses current approaches in the literature which have demonstrated effective drug delivery in controlled environments. Finally, each chapter contains several sections on "Clinical Applications" which describe the validity of materials approaches from a clinical perspective; these sections review the safety and efficacy of drug delivery systems for specific, compelling medical applications. The book thereby bridges materials science with clinical medicine, and provides the reader with a bench-to-bedside view of novel drug delivery systems. * Provides a comprehensive description of drug delivery systems from a materials perspective * Includes a wide-ranging discussion of clinical applications of drug delivery systems * Presents separate chapters on controlled release materials, thin film materials, self-microemulsifying materials, smart materials, etc. * Covers fundamental engineering principles, rational materials design, implementation testing, and clinical applications for each material type

Prozac. Paxil. Zoloft. Turn on your television and you are likely to see a commercial for one of the many selective serotonin reuptake inhibitors (SSRIs) on the market. We hear a lot about them, but do we really understand how these drugs work and what risks are involved for anyone who uses them? Let Them Eat Prozac explores the history of SSRIs-from their early development to their latest marketing campaigns-and the controversies that surround them. Initially, they seemed like wonder drugs for those with mild to moderate depression. When Prozac was released in the late 1980s, David Healy was among the psychiatrists who prescribed it. But he soon observed that some of these patients became agitated and even attempted suicide. Could the new wonder drug actually be making patients worse? Healy draws on his own research and expertise to demonstrate the potential hazards associated with these drugs. He intersperses case histories with insider accounts of the research leading to the development and approval of SSRIs as a treatment for depression. Let Them Eat Prozac clearly demonstrates that the problems go much deeper than a side-effect of a particular drug. The pharmaceutical industry would like us to believe that SSRIs can safely treat depression, anxiety, and a host of other mental problems. But, as Let Them Eat Prozac reveals, this "cure" may be worse than the disease.

This book describes the newest developments in antibody drug conjugates and immunotoxins, paving their way to clinical application. Lessons learned from the current state of the art are used to further improve our understanding of their mechanisms of action and off target activities. The book introduces scientists to all of the prerequisites that must be properly addressed, including identification of the right target, specific traits of target binding antibodies, proper selection of the toxic payload, internalization induced by binding, and next generation conjugation and linker technologies. These knowledge-based, revolutionary new drug principles will form the cornerstone of the future standard of care and will lead to major advances in application, as well as improved quality of life and patient survival rates. This book will be of interest to biotech companies and researchers working in the fields of immunology, pharmacology, and oncology.

This book is designed to focus on the role of Calcitonin Gene-Related Peptide (CGRP) in health and disease. This peptide, originally discovered in the 1980s as a sensory neuropeptide with cardiovascular effects, is now known to play a distinct role in the pain processing of migraine. The various chapters address the origin, localization and function of CGRP and its receptor in the peripheral nervous system, in the cardiovascular system, and in other tissues and organs. Further attention is paid to the drug discovery pathway where recent findings show the beneficial effect of small molecule antagonists of the CGRP receptors for the relief of the migraine attack and of monoclonal antibodies against CGRP or the CGRP receptor for migraine prevention.